Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deramiocel - Capricor Therapeutics

Next Previous
Drug Profile

Deramiocel - Capricor Therapeutics

Alternative Names: Allogeneic adult stem cell therapy for myocardial infarction - Capricor; Allogeneic cardiosphere-derived cells - Capricor; Allogeneic CDCs - Capricor; Allogenic derived cells - Capricor; CAP-1002

Latest Information Update: 25 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capricor
  • Developer Capricor; Capricor Therapeutics; Medical University of South Carolina
  • Class Exosome therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Duchenne muscular dystrophy
  • Phase II COVID 2019 infections
  • Phase I/II Cardiomyopathies
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 25 Aug 2025 Capricor Therapeutics scheduled a Type A meeting with the US FDA to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy
  • 11 Aug 2025 Capricor Therapeutics plans a Type A meeting with the US FDA to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy in August 2025
  • 11 Aug 2025 Capricor Therapeutics submits a protocol amendment to designate left ventricular ejection fraction (LVEF) as the primary efficacy endpoint of the phase III HOPE-3 trial in Duchenne muscular dystrophy (DMD) prior to August 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top